Cargando…
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in...
Autores principales: | Gogineni, Vinaya, Morand, Susan, Staats, Hannah, Royfman, Rachel, Devanaboyina, Monika, Einloth, Katelyn, Dever, Danielle, Stanbery, Laura, Aaron, Phylicia, Manning, Luisa, Walter, Adam, Edelman, Gerald, Dworkin, Lance, Nemunaitis, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738841/ https://www.ncbi.nlm.nih.gov/pubmed/33391401 http://dx.doi.org/10.7150/jca.49406 |
Ejemplares similares
-
Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021) -
FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020) -
NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
por: Devanaboyina, Monika, et al.
Publicado: (2022) -
Resident Memory T Cells and Their Effect on Cancer
por: Craig, Daniel J., et al.
Publicado: (2020) -
Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)